Chronic Spontaneous Urticaria

Cardiovascular·MeSH: Pruritus

23 drugs in development·12 companies·20 clinical trials

Drug Pipeline by Phase

Phase 3(11)

Drug	Company
Barzolvolimab (CDX-0159)	Celldex Therapeutics, Inc. (CLDX)
bgb-16673	BeOne Medicines Ltd. (ONC)
BGB-16673	BeOne Medicines Ltd. (ONC)
dupilumab	Novartis AG (NVS)
dupilumab	NOVARTIS AG (NVSEF)
JYB1904	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
lou064	Novartis AG (NVS)
non sedating h1-antihistamine	Sanofi (SNY)
omalizumab	Novartis AG (NVS)
omalizumab	NOVARTIS AG (NVSEF)
Remibrutinib	Novartis AG (NVS)

Phase 2(7)

Drug	Company
barzolvolimab	Celldex Therapeutics, Inc. (CLDX)
briquilimab	Jasper Therapeutics Inc. (JSPR)
evo756	Evommune, Inc. (EVMN)
intranasal epinephrine technology product candidates	ARS Pharmaceuticals, Inc. (SPRY)
lou064	Novartis AG (NVS)
oral evo756	Evommune, Inc. (EVMN)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

Phase 1(1)

Drug	Company
ak006	Allakos Inc. (ALLK)

Preclinical(1)

Drug	Company
EPS-1421	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 4(3)

BioSniper tracks 23 drugs in development for Chronic Spontaneous Urticaria across 12 companies.

There are 20 clinical trials targeting Chronic Spontaneous Urticaria tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.